Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
Study Identifier
190342-032D
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Study Details
Medical Condition
Study Drug
Phase
Phase 2
Sex
Female & Male
Age
50+ years
Protocol Summary
Stage 1 is a patient-masked, dose-escalation, safety evaluation of brimonidine intravitreal implant. Patients will receive implant in one eye and "sham" treatment (meaning no treatment) in the fellow eye. Stage 2 will begin after 1 month of safety has been evaluated for Stage 1. Stage 2 is a randomized, double-masked, dose-response, sham-controlled evaluation of the safety and efficacy of brimonidine intravitreal implant in patients with geographic atrophy from age-related macular degeneration. Patients will be followed for up to 2 years.
Study Locations
Location
Status
Location
Abilene, Texas, United States
Status
Not applicable
Location
Sydney, New South Wales, Australia
Status
Not applicable
Location
Karlsruhe, Germany
Status
Not applicable
Location
Udine, Italy
Status
Not applicable
Location
Makati City, Philippines
Status
Not applicable
Location
Coimbra, Portugal
Status
Not applicable
Showing {first} - {last} of {total} Results